Lip, P L
Cikatricis, P
Sarmad, A
Damato, E M
Chavan, R
Mitra, A
Elsherbiny, S
Yang, Y
Mushtaq, B
Article History
Received: 4 March 2017
Accepted: 5 September 2017
First Online: 3 November 2017
Competing interests
: PLL is a speaker for Norvatis. PC is a travel-sponsorship recipient from Allergan and Norvatis. EMD is a speaker for Norvatis. AM is an Advisory Board Member of and speaker for Alimera Sciences. SE is an Advisory Board Member of and speaker for Alimera Science, Bayer, Novartis, and Alcon. YY is an Advisory Board Member of and speaker for Alimera Science, Allergan, Bayer, Novartis, Pfizer, and Thrombogenics. BM is an Advisory Board Member of and speaker for Alimera Science, Allergan, Bayer, Novartis, and ORAYA therapeutics. The other authors declare no conflict of interest.